Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient ...

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

By Kunal Das and Puyaan Singh July 21 (Reuters) - Agios Pharmaceuticals said on Tuesday it is discontinuing development of ...

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...

Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...

Disclosure: Conran has received grants from the Sao Paulo Research Foundation and Novartis AG; and participated in data safety monitoring or advisory boards for Novo Nordisk. Rees has participated on ...

German family-owned drugmaker Grünenthal has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a ...

BACKGROUND: Metabolic adaptation and maladaptation are hallmarks of the failing heart and may be a target for therapeutic ...

Autoantibodies are central to the diagnosis, classification, and stratification of many autoimmune diseases, particularly ...